Overview

Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Comparison of the pharmacokinetics/Pharmacodynamics of the SHR3824 in Patients With Mild, Moderate and Severe Hepatic Impairment Compared with Healthy Volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.